Compare MIRM & IRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | IRT |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.9B |
| IPO Year | 2019 | 2013 |
| Metric | MIRM | IRT |
|---|---|---|
| Price | $79.34 | $17.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $92.45 | $21.56 |
| AVG Volume (30 Days) | 809.5K | ★ 2.7M |
| Earning Date | 11-04-2025 | 02-11-2026 |
| Dividend Yield | N/A | ★ 3.83% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | $471,794,000.00 | ★ $662,924,000.00 |
| Revenue This Year | $53.78 | $4.21 |
| Revenue Next Year | $19.91 | $4.79 |
| P/E Ratio | ★ N/A | $195.01 |
| Revenue Growth | ★ 53.66 | 3.19 |
| 52 Week Low | $36.88 | $15.07 |
| 52 Week High | $82.58 | $21.87 |
| Indicator | MIRM | IRT |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 59.40 |
| Support Level | $77.99 | $17.25 |
| Resistance Level | $82.58 | $17.79 |
| Average True Range (ATR) | 3.21 | 0.24 |
| MACD | 1.03 | 0.05 |
| Stochastic Oscillator | 83.25 | 71.93 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Louisville, Memphis, Atlanta, and Raleigh. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.